Antibiotic News and Research

RSS
Scientists uncover new pharmaceutical strategy for treating melanoma

Scientists uncover new pharmaceutical strategy for treating melanoma

Symbiomix closes $41 million Series A financing and reports positive results from SYM-1219 Phase 2 trial

Symbiomix closes $41 million Series A financing and reports positive results from SYM-1219 Phase 2 trial

Lymphatic pump treatment may fight pneumonia by enhancing efficacy of antibiotics

Lymphatic pump treatment may fight pneumonia by enhancing efficacy of antibiotics

New research-based pharmaceutical industry report provides insights on how to slow down antimicrobial resistance (AMR) and boost antibiotic R&D

New research-based pharmaceutical industry report provides insights on how to slow down antimicrobial resistance (AMR) and boost antibiotic R&D

New research-based pharmaceutical industry report provides insights on how to slow down antimicrobial resistance (AMR) and boost antibiotic R&D

New research-based pharmaceutical industry report provides insights on how to slow down antimicrobial resistance (AMR) and boost antibiotic R&D

New device can turn smartphone into DNA-scanning fluorescent microscope

New device can turn smartphone into DNA-scanning fluorescent microscope

Papers on antibiotic resistance, neglected diseases and future of the ocean to be discussed during G7 summit

Papers on antibiotic resistance, neglected diseases and future of the ocean to be discussed during G7 summit

1 in 5 nursing home residents with dementia harbor strains of drug-resistant bacteria

1 in 5 nursing home residents with dementia harbor strains of drug-resistant bacteria

New WHO report analyzes global response to antimicrobial resistance

New WHO report analyzes global response to antimicrobial resistance

New Johns Hopkins study finds occurrence of gonorrhea or chlamydia is significant in women

New Johns Hopkins study finds occurrence of gonorrhea or chlamydia is significant in women

Luminex provides clinical trial update on ARIES HSV 1&2 Assay

Luminex provides clinical trial update on ARIES HSV 1&2 Assay

TAXIS Pharmaceuticals' TXA709 compound shows promise in combating antibiotic resistance

TAXIS Pharmaceuticals' TXA709 compound shows promise in combating antibiotic resistance

Preclinical data from Synthetic Biologics' SYN-005 for Pertussis treatment presented at ECCMID 2015

Preclinical data from Synthetic Biologics' SYN-005 for Pertussis treatment presented at ECCMID 2015

U-M study: Nearly half of American hospitals not taking key steps to prevent C. diff infections

U-M study: Nearly half of American hospitals not taking key steps to prevent C. diff infections

Actavis reports positive results from phase 3 study of single-dose DALVANCE for treatment of ABSSSI

Actavis reports positive results from phase 3 study of single-dose DALVANCE for treatment of ABSSSI

Leading scientists warn of 'Antibiotic Armageddon' in Britain and Europe by 2025

Leading scientists warn of 'Antibiotic Armageddon' in Britain and Europe by 2025

Findings suggest development of 'post-infection' vaccine to reduce TB rates in China

Findings suggest development of 'post-infection' vaccine to reduce TB rates in China

Alltech enters into agreement to acquire Ridley

Alltech enters into agreement to acquire Ridley

Debiopharm announces initiation of Debio 1450 phase II study for treatment of ABSSSI

Debiopharm announces initiation of Debio 1450 phase II study for treatment of ABSSSI

Rising shortages of key antibiotics raise serious concerns about effects on patient care

Rising shortages of key antibiotics raise serious concerns about effects on patient care

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.